Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Amendments to Rule 23 (1)
- Class actions (1)
- Congress (1)
- Conservative legal movement (1)
- Courts (1)
-
- Empirical research (1)
- Federal regulation (1)
- Litigation reform (1)
- Polarization (1)
- Politics & ideology of judiciary (1)
- Preemption (1)
- Private enforcement of rights (1)
- Product safety (1)
- Products liability (1)
- Restrictions on private enforcement of legislation (1)
- Rules Enabling Act (1)
- SCOTUS (1)
- Supreme Court (1)
- Torts (1)
Articles 1 - 2 of 2
Full-Text Articles in Legal Remedies
Rights And Retrenchment In The Trump Era, Stephen B. Burbank, Sean Farhang
Rights And Retrenchment In The Trump Era, Stephen B. Burbank, Sean Farhang
All Faculty Scholarship
Our aim in this essay is to leverage archival research, data and theoretical perspectives presented in our book, Rights and Retrenchment: The Counterrevolution against Federal Litigation, as a means to illuminate the prospects for retrenchment in the current political landscape. We follow the scheme of the book by separately considering the prospects for federal litigation retrenchment in three lawmaking sites: Congress, federal court rulemaking under the Rules Enabling Act, and the Supreme Court. Although pertinent data on current retrenchment initiatives are limited, our historical data and comparative institutional perspectives should afford a basis for informed prediction. Of course, little in …
The Fda And The Tort System: Postmarketing Surveillance, Compensation, And The Role Of Litigation, Catherine T. Struve
The Fda And The Tort System: Postmarketing Surveillance, Compensation, And The Role Of Litigation, Catherine T. Struve
All Faculty Scholarship
The dispute over FDA regulatory preemption is familiar: Preemption advocates assert that products liability suits stifle innovation, and proponents of tort liability counter that the FDA fails adequately to protect the public and that persons injured by defective products deserve compensation. The FDA's premarket approval process cannot detect all potential safety problems with a new drug; postmarketing surveillance is essential, and the FDA's efforts in that regard fall short. Advocates of preemption will find it difficult to establish that FDA regulation should entirely displace the tort system. This article examines whether a case could be made for an intermediate approach …